Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ: CMND )

1.440 -0.050 (-3.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 160,102
Open 1.500
Bid (Size) 1.460 (3)
Ask (Size) 1.470 (5)
Prev. Close 1.490
Today's Range 1.410 - 1.500
52wk Range 0.9205 - 3.580
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clearmind Medicine Announces Shareholders Meeting Results
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-0.69%
-0.69%
1 Month
+0.70%
+0.70%
3 Month
+2.86%
+2.86%
6 Month
-7.69%
-7.69%
1 Year
-30.43%
-30.43%

More News

Read More
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Is Penny Stock Clearmind Gaining Today?
Via Benzinga
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
From Clearmind Medicine Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.